HIV Genetic Diversity and Drug Resistance
AbstractMost of the current knowledge on antiretroviral (ARV) drug development and resistance is based on the study of subtype B of HIV-1, which only accounts for 10% of the worldwide HIV infections. Cumulative evidence has emerged that different HIV types, groups and subtypes harbor distinct biological properties, including the response and susceptibility to ARV. Recent laboratory and clinical data highlighting such disparities are summarized in this review. Variations in drug susceptibility, in the emergence and selection of specific drug resistance mutations, in viral replicative capacity and in the dynamics of resistance acquisition under ARV selective pressure are discussed. Clinical responses to ARV therapy and associated confounding factors are also analyzed in the context of infections by distinct HIV genetic variants. View Full-Text
Share & Cite This Article
Santos, A.F.; Soares, M.A. HIV Genetic Diversity and Drug Resistance. Viruses 2010, 2, 503-531.
Santos AF, Soares MA. HIV Genetic Diversity and Drug Resistance. Viruses. 2010; 2(2):503-531.Chicago/Turabian Style
Santos, André F.; Soares, Marcelo A. 2010. "HIV Genetic Diversity and Drug Resistance." Viruses 2, no. 2: 503-531.